-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UwI+CAO5vaNmcnqIMHQIoaoPyNuELgYivOM1aF5L+u8lgFBd3rhQxljmcIZVCbnx
 ovuL8WehaniwSZKDHsp98w==

<SEC-DOCUMENT>/in/edgar/work/20000829/0000950133-00-003605/0000950133-00-003605.txt : 20000922
<SEC-HEADER>0000950133-00-003605.hdr.sgml : 20000922
ACCESSION NUMBER:		0000950133-00-003605
CONFORMED SUBMISSION TYPE:	RW
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20000829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GUILFORD PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000918066
		STANDARD INDUSTRIAL CLASSIFICATION:	 [2834
]		IRS NUMBER:				521841960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231
</COMPANY-DATA>

		FILING VALUES:
			FORM TYPE:		RW
			SEC ACT:		
			SEC FILE NUMBER:	333-39546
			FILM NUMBER:		712923
</FILING-VALUES>

			BUSINESS ADDRESS:	
				STREET 1:		6611 TRIBUTARY ST
				CITY:			BALTIMORE
				STATE:			MD
				ZIP:			21224
				BUSINESS PHONE:		4106316300
</BUSINESS-ADDRESS>
</FILER>
</SEC-HEADER>
<DOCUMENT>
<TYPE>RW
<SEQUENCE>1
<FILENAME>rw.txt
<DESCRIPTION>REQUEST FOR WITHDRAWAL OF REGISTRATION STATEMENT
<TEXT>

<PAGE>   1

                         GUILFORD PHARMACEUTICALS INC.

                                August 28, 2000

Securities and Exchange Commission
Judiciary Plaza
Mail Stop 3-9
450 Fifth Street, N.W.
Washington, D.C. 20549
Attn: Jeffrey Riedler


         Re:      Guilford Pharmaceuticals Inc.
                  Registration Statement on Form S-4
                  SEC File No. 333-39546
                  Filed on June 16, 2000

Dear Mr. Riedler:

         We hereby request the withdrawal of our Registration Statement on Form
S-4 and Joint Proxy Statement (the "Form S-4"), filed with the Securities and
Exchange Commission on June 16, 2000, because the Agreement and Plan of Merger
and Reorganization, dated May 29, 2000, by and among Guilford Pharmaceuticals
Inc. and Gliatech Inc., has been terminated. No offers or sales of securities
were made with respect to the Form S-4.

         Please call Stephanie D. Marks at (410) 659-2767 with any questions
that you may have.

                                               Very truly yours,

                                               GUILFORD PHARMACEUTICALS INC.

                                               By: /s/ Thomas C. Seoh

                                               Thomas C. Seoh
                                               Senior Vice President, General
                                               Counsel and Secretary
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----